Insilico Medicine and SK Biopharmaceuticals announced a $2.5 billion AI-driven collaboration at BIO 2026 to discover neuroimmune disorder candidates for CNS indications. Insilico will apply its Pharma.AI platform, while SK Biopharmaceuticals will take responsibility for late-stage development and commercialization. The agreement structures both upfront and milestone payments, with additional value tied to development, regulatory and commercial outcomes. The partnership adds to Insilico’s expanding web of major pharmaceutical collaborations as AI models move from discovery into clinically oriented programs. Bio 2026 coverage also emphasized how biotechs are adopting AI for faster knowledge extraction and target identification, with companies reporting reduced time-to-target and near-term cost expectations as toolchains become more operationalized.